 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Participation in Clinical Trials
The Institute is currently enrolling subjects at a rate of greater than 120 per year on active clinical trials, from a base of 2400 new cancer patients seen in the NGOC practice annually. Accrual rates are expected to be enhanced through the recent expansion of coordinators and technology support of the ACORN network. The Institute is now able to support a variety of clinical trials in cancer and blood disorders, particularly in Phases II, III, and IV of Investigational Drug development. Available services include on-site blood draw, hematology lab, centrifuge, specimen refrigeration, dedicated IND storage, examination rooms, infusion therapy, and adjacent 24/7 hospital support.
Potential Risks and Benefits
Only you can decide whether or not to take part in a clinical study. Research Trials are closely monitored and follow strict guidelines, including informing interested patients about the risks and benefits before deciding whether to take part in a study (informed consent). Your physician can advise you about your eligibility to participate in clinical studies. Disease type, overall health, age and other individual factors determine your eligibility.
Potential Benefits include:
- Access to new drugs before they are available to the public
- Close monitoring of your progress
- A more active role in your healthcare
- You may be among the first to benefit if the approach being studied is found to be helpful
- The opportunity to make a valuable contribution to cancer research
Potential Risks may include:
- New drugs may have side effects or risks unknown to the doctors
- New drugs may not work or may not work as well
- Even if a new approach has benefits, it may not work for you